Tucatinib

Overview

Tucatinib (Irbinitinib) is a potent, orally active and selective HER2 inhibitor with an IC 50 of 8 nM.

Application

Products | Products > Disease Areas > Hepatitis Virus Infection | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Hepatitis C Virus Infection | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > EGFR

Product Information

• Catalog No.: HY-16069
• CAS No.: 937263-43-9
• Molecular Formula: C26H24N8O2
• Molecular Weight: 480.52
• Purity: 99.48%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.62 mg/mL (5.45 mM); Clear solution
• Availability: In-stock

Source

Original product source